Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study

[1]  Yeun-Chung Chang,et al.  Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT. , 2005, Radiology.

[2]  Khamitov Ra,et al.  Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures , 2008 .

[3]  V. A. Maksimov,et al.  [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures]. , 2008, Voprosy virusologii.

[4]  D. Barnard,et al.  Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy. , 2011, Future virology.

[5]  V. Leyva-Grado,et al.  Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections , 2019, Front. Microbiol..

[6]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[7]  Z. Hong,et al.  Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study , 2020, Journal of Infection.

[8]  E. Fish,et al.  Interferon-α2b Treatment for COVID-19 , 2020, Frontiers in Immunology.

[9]  Jianjun Gao,et al.  Discovering drugs to treat coronavirus disease 2019 (COVID-19). , 2020, Drug discoveries & therapeutics.

[10]  T. A. Zhuravleva,et al.  Antioxidant Potential of Antiviral Drug Umifenovir , 2020, Molecules.

[11]  Pengfei Sun,et al.  Clinical characteristics of hospitalized patients with SARS‐CoV‐2 infection: A single arm meta‐analysis , 2020, Journal of medical virology.

[12]  George Nicolae Daniel Ion,et al.  Comprehensive analysis of drugs to treat SARS-CoV-2 infection: Mechanistic insights into current COVID-19 therapies (Review) , 2020, International journal of molecular medicine.

[13]  M. E. El Zowalaty,et al.  From SARS to COVID-19: A previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans – Call for a One Health approach , 2020, One Health.

[14]  Hongzhou Lu,et al.  Drug treatment options for the 2019-new coronavirus (2019-nCoV). , 2020, Bioscience trends.

[15]  Jizhen Ren,et al.  Clinical characteristics of hospitalized patients with SARS‐CoV‐2 infection: A single arm meta‐analysis , 2020, Journal of medical virology.

[16]  Feng He,et al.  Coronavirus disease 2019: What we know? , 2020, Journal of medical virology.

[17]  Hongzhou Lu,et al.  Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia , 2020 .